9T Labs Raises $17M Series A Funding

9T Labs: Composite equipment and software OEM 9T Labs AG announced today that it closed its Series A funding round and raised $17-million USD to help further commercialize the company’s innovative Red Series® Additive Fusion SolutionTM platform for the production of advanced carbon fiber-reinforced thermoplastic (CFRTP) composite parts.

Key investors include the world’s leading 3D printing company Stratasys, the venture capital arm of high-performance thermoplastic composites supplier Solvay SA (Solvay Ventures), as well as VC investors Verve Ventures, ACE & Company, Zürcher Kantonalbank and Wingman Ventures.

9T Labs’ technology platform enables desktop size high-performance structural parts to be produced in CFRTP composites in production volumes ranging from 100 to over 100,000 parts/year. By combining software, 3D printing — offering unexcelled design freedom, part complexity, and control of fiber orientation — with compression molding in matched metal dies – providing rapid cycle times, high production rates, excellent surface finishes and low voids, plus high repeatability and reproducibility (R&R) — 9T Labs’ Red Series platform offers the best of both additive and existing manufacturing to create a more sustainable and high-performance alternative to traditional metal and plastic manufacturing technologies.

It is used by Fortune 500 aerospace companies to lightweight its future mobility programs, by medical corporations to reduce material waste for manufacturing medical instruments and by the leisure and luxury industry to provide consumer products with increased functionality. The global 3D printing market is predicted to grow at a compounded annual growth rate (CAGR) of 25% to exceed a value of $100-billion USD by 2030 in the $2-trillion USD global parts manufacturing segment.

9T Labs has combined the simplicity of 3D printing with the strength of continuous carbon fiber composites, and that’s an exciting development for our industry,” said Adam Pawloski, VP Manufacturing Solutions at Stratasys. “Their Additive Fusion Technology leverages the benefits of printing, automated tape laying, and compression molding to deliver fully dense parts with multidirectional reinforcement. Moreover, this technology scales to the volumes of production parts needed by serial manufacturers. The end result is a solution with the potential to dramatically shift the industry away from metal and towards composite parts.”

“As a leading supplier of thermoplastic composites technologies, we are excited to contribute our materials expertise to help accelerate 9T Labs’ developments in the 3D printing space to produce structural composite parts,” adds Fabrizio Ponte, head of Thermoplastic Composites Platform, Solvay SA.

Following the investment round, John Hartner, former Chief Executive Officer of ExOne (Pittsburgh, PA, USA) will join 9T Labs’ board of director as chairman. Hartner is an experienced leader with more than 30 years’ involvement in the automation, semiconductor, clean tech, and 3D printing industries. “I have been impressed by the company’s unique solution and am very excited to help the team to bring this technology to manufacturing companies around the world” notes Hartner.

The money raised during the Series A investment round will be used to fund the next phase of growth at 9T Labs to help its customers ramp up their applications to mass volumes, complement the current material portfolio, and develop future technology platforms. “This round of investment and the combined expertise with our partners will allow us to make the next big leap in commercialization and fulfilling our mission to enable widespread replacement of metal parts with fully recyclable high-performance carbon composite materials,” adds Martin Eichenhofer, 9T Labs co-founder and CEO.

“Through this support, we will be able to demonstrate things we could not have imagined 10 years ago.”

Source9T Labs

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”